Sanofi Posts Rises in 1Q Sales, Net Profit
26 Abril 2019 - 1:05AM
Noticias Dow Jones
By Donato Paolo Mancini
Sanofi SA (SAN.FR) said Friday that net profit and sales both
increased in the first quarter, and backed its full-year guidance
as the pharmaceutical giant reaps the benefits from its investment
in specialty care.
Business net income, an important adjusted net profit metric for
the French pharma company, was 1.77 billion euros ($1.97 billion),
or EUR1.42 a share, up 9% at constant exchange rates. IFRS net
profit was EUR1.14 billion, or EUR0.91 a share.
Sales were EUR8.39 billion, buoyed by specialty care and
vaccines. Analysts had expected sales of EUR8.45 billion. Sales in
the diabetes franchise declined 6.9%.
Sanofi backed its outlook for the 2019 business EPS, expecting
it to grow between 3% and 5%.
The company's chief financial officer, Jean-Baptiste de
Chatillon, said Sanofi wasn't expecting any major impact from
ramped-up rhetoric as concerns healthcare reform in the U.S., after
the Democrats floated a Medicare for All plan that could upend the
industry.
Write to Donato Paolo Mancini at
donatopaolo.mancini@dowjones.com
(END) Dow Jones Newswires
April 26, 2019 01:50 ET (05:50 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
